Compare ZLAB & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | MGNI |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | China | United States |
| Employees | N/A | 514 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2017 | 2014 |
| Metric | ZLAB | MGNI |
|---|---|---|
| Price | $16.62 | $14.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $49.60 | $25.22 |
| AVG Volume (30 Days) | 793.9K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 493.75 |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $460,156,000.00 | $156,414,000.00 |
| Revenue This Year | $9.75 | $6.28 |
| Revenue Next Year | $26.03 | $9.76 |
| P/E Ratio | ★ N/A | $495.33 |
| Revenue Growth | 15.33 | ★ 25.45 |
| 52 Week Low | $15.96 | $10.82 |
| 52 Week High | $44.34 | $26.65 |
| Indicator | ZLAB | MGNI |
|---|---|---|
| Relative Strength Index (RSI) | 31.99 | 59.32 |
| Support Level | $15.96 | $13.61 |
| Resistance Level | $19.64 | $15.25 |
| Average True Range (ATR) | 0.62 | 0.68 |
| MACD | -0.17 | 0.12 |
| Stochastic Oscillator | 8.85 | 70.30 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.